Antibodies patentsBulk PDF Downloads |
This page is updated frequently with new Antibodies-related patent applications.
  Cancer markers and methods of use thereofThe present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid ssea-3/ssea-4/globoh in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4galt; beta-4galnact-i; or beta-3galt-v enzymes in the globoseries synthetic pathway. Academia Sinica |
 Methods and products for the diagnosis and prognosis of ovarian tumor malignancyThe present invention relates to methods and products for the diagnosis and prognosis of ovarian tumor malignancy based on procol11a1 protein which is expressed in malignant ovarian tumors but not in non-tumoral ovarian tissue or in situ or benign or borderline ovarian tumors. Procol11a1-specific antibodies can be used for high sensitivity and specificity diagnosis of ovarian cancer as well as for differentiating malignant ovarian tumors from benign or in situ tumors, and for the prognosis of ovarian tumor malignancy and for predicting borderline tumor malignancy. Oncomatrix, S.l. |
 Compositions and methods for prostate cancer analysisThe invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-steap-1 antibodies and uses thereof.. Genentech, Inc. |
 Soluble hiv-1 envelope glycoprotein trimersThe present application relates to novel hiv-1 envelope glycoproteins which may be utilized as an hiv-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.. The Scripps Research Institute |
 Antibodies for tumor gangliosidesHigh affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The Government Of The United States As Represented By The Secretary Of Health |
 Method of treating a pathological syndrome and a pharmaceutical agentPharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.. |
 Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereofAn antibody or antigen-binding fragment thereof which specifically binds the α3 domain of a hla-g protein, in particular binds the β2-microglobulin free hla-g protein exhibiting an α3 domain. The nucleic acid molecules encoding a human hla-g α3 domain polypeptide, which is selected from a group of specific sequences, and vectors for the cloning and/or expression of such nucleic acid molecules, recombined cells or cell lines and compositions for use in a host in need thereof to interfere with and neutralize the immune down-regulation due to hla-g proteins, and/or improving or treating conditions showing hla-g+ lesions, and/or improving or treating a neoplasic condition or disease. Invectys |
 Novel modulators and methods of useNovel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.. . Stemcentrx, Inc. |
 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicityThe present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.. Roche Glycart Ag |
 Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseasesThe present disclosure relates to a method of inhibiting fibrocyte or profibrotic macrophage formation by administering a cd209-binding compound or antibody to monocytes in a target location in an amount and for a time sufficient to suppress formation of fibrocytes or profibrotic macrophages from the monocytes. It also relates to compounds and pharmaceutical formulations for use in such methods. |
| The present invention is based, in part, on the discovery of monoclonal antibodies that specifically bind to the cytoplasmic domain of pd-l1 antibodies useful for diagnostic, prognostic, and therapeutic applications, as well as immunoglobulins polypeptides, and nucleic acids thereof.. . Dana-farber Cancer Institute Inc. |
| Provided herein are compositions (e.g., killer cell immunoglobulin-like receptor (kir)-targeting agents) that target a subset of t lymphocytes present in disease states (e.g., lupus and other autoimmune diseases) and methods of treating conditions and/or diseases therewith. In particular, anti-kir antibodies, fragments thereof, or related compositions are provided for the treatment of conditions and/or diseases (e.g., lupus and other autoimmune diseases, atherosclerosis, etc.).. The Regents Of The University Of Michigan |
| This invention provides antibodies or functional fragments thereof that bind to pd-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention. Junmeng Biosciences Co., Ltd |
| The present invention relates to vstm5-specific antibodies, antibody fragments, and vstm5 polypeptides, conjugates and compositions comprising same, for modulating (antagonizing or agonizing) one or more of the effects of vstm5 expression on immunity. More specifically, the present invention relates to vstm5-specific antibodies, antibody fragments, and vstm5 polypeptides, conjugates and compositions comprising same for treating and aiding in the diagnosis of cancer, infectious diseases and immune related diseases, e.g., those associated with aberrant (higher or lower than normal) vstm5 expression by diseased and/or immune cells and/or aberrant (increased or reduced) vstm5-mediated effects on immunity.. Compugen Ltd. |
| Novel anti-il-13 antigen-binding proteins such as antibodies and antigen-binding fragments thereof are provided. Methods of using the proteins to reduce il-13 activity and to treat il-13-associated diseases and conditions are further provided.. Medimmune Limited |
| An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human tnf. Such binding disrupts assembly of the monomer into bioactive trimeric human stnf. Thymon, Llc |
| Tnf-α binding proteins, including chimeric, cdr-grafted, and humanized antibodies that bind tnf-α are provided. Binding proteins have high affinity for tnf-α and neutralize tnf-α activity. Abbvie Inc. |
| Anti-nerve growth factor antibodies and methods of preparing and using the same A method of preparing an antibody suitable for use in a feline is provided. Also provided are chimeric and felinised antibodies which specifically bind to feline neuronal growth factor (ngf) and neutralise the ability of feline ngf to bind to the p75 or trka feline ngf receptor. Nvip Pty Ltd |
| The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component c5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions. Alexion Pharmaceuticals, Inc. |
Order a batch download of a huge number of patent PDFs.
Bulk PDF Downloads
This is a premium service.
|
| Regulating bacillus anthracis lethal factor activity via an activating epitope region Provided are antibodies capable of binding to a particular epitope or specifically binding to lf or ltx and enhancing the activity of the lf or ltx relative to the lf or ltx absent the antibody binding.. . The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
| This application relates to methods for purification of proteins such as antibodies using a hydrophilic polymer (e.g., peg), a fatty acid (e.g., caprylic acid), and/or another agent (e.g., calcium chloride).. . Universitat Fur Bodenkultur Wein |
| Embodiments of the present invention are directed to high throughput flow through purification of antibodies using mixed mode chromatography.. . Abbvie Inc. |
| Combination of aurora kinase inhibitors and anti-cd20 antibodies The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering aurora kinase inhibitors in combination with anti-cd20 antibodies.. Millennium Pharmaceuticals, Inc. |
| Method of inducing the production of protective anti-hiv-1 antibodies The present invention relates, in general, to an immunogen for hiv vaccination and, in particular, to a method of inducing the production of protective anti-hiv antibodies by targeting b cell germline and clone intermediates using a combination of hiv envelope and non-hiv immunogens. The invention also relates to compositions suitable for use in such a method.. Duke University |
| Provided herein are hiv vaccines that encompasses recombinant trimers that mimic native hiv-1 envelope trimers. Also provided are methods of administering to a subject in need thereof an hiv vaccine provided herein to elicit antibodies against a recombinant trimer in the subject. The Catholic University Of America |
| The present invention is directed to novel anti-cancer compounds and methods of treating and/or inhibiting cancer in patients, including metastatic cancer, recurrent cancer and drug resistant cancers, including multiple drug resistant cancers. Compounds according to the present invention provide anti-cancer activity, at least in part, by virtue of their nucleotide intercalating activity through the use of analogs of (−)lomaiviticin a, a potent anticancer agent which exhibits cytotoxicity through its principal mechanism of cleavage and to a lesser extent, its intercalation of cellular polynucleotides, especially dna. Yale University |
| A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Yale University |
antibodies, immunoassay methods and kits thereof are described for the detection and determination of 3-(aminomethyl)-5-methylhexanoic acid. The novel immunogens from which said antibodies are generated are also described.. Randox Laboratories Limited |
Methods, compositions, systems, and devices are provided for performing and analyzing agglutination assays. In one aspect, methods for image analysis of agglutination assays are provided. Theranos, Inc. |
antibodies, and antibody pairs, that bind and specifically detection pre-haptoglobin-2, and methods for their use, are provided.. . Bio-rad Laboratories, Inc. |
Infectious genomic dna clone and serological profile of torque teno sus virus 1 and 2 The present invention also provides infectious dna clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of torque teno sus virus (ttsuv). The present invention also provides methods for diagnosing ttsuv infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (elisa) and western blot using pttv specific antigens for detecting serum pttv specific antibodies which indicate infections ttsuv1, ttsuv2, and individual ttsuv1 genotypes.. Virginia Tech Intellectual Properties |
The present invention relates to dna sequences encoding vmp-like polypeptides of pathogenic borreliae, the use of the dna sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the dna and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, dna segments and antibodies.. Board Of Regents, The University Of Texas System |
A disposable, virus-trapping membrane, and a corresponding method to remove viruses from solution are described. The membrane includes a disposable, micro-porous filter membrane and a ligand immobilized on the membrane. Wisconsin Alumni Research Foundation |
The invention relates to the purification of bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule from a mixture of monospecific antibodies. The bispecific antibodies are composed of a single heavy chain and two different light chains, one containing a kappa constant domain and the other a lambda constant domain. Novimmune Sa |
The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.. Siamab Therapeutics, Inc. |
In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an actriib signaling pathway. Examples of such antagonists include actriib polypeptides, anti-actriib antibodies, anti-activin a and/or b antibodies, anti-myostatin antibodies, anti-gdf3 antibodies, and anti-bmp7 antibodies. Acceleron Pharma Inc. |
The invention relates to human neutralizing anti-kit antibodies and uses thereof. More particularly, the invention relates to an antibody comprising a heavy chain variable region comprising seq id no: 2 in the h-cdr1 region, seq id no: 3 in the h-cdr2 region and seq id no: 4 in the h-cdr3 region; and a light chain variable region comprising seq id no: 6 in the l-cdr1 region, seq id no: 7 in the l-cdr2 region and seq id no: 8 in the l-cdr3 region. Ecole Normale SupÉrieure De Cachan |
Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member erbb3/her3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of erbb3/her3.. Aveo Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. Ibc Pharmaceuticals, Inc. |
Order a batch download of a huge number of patent PDFs.
Bulk PDF Downloads
This is a premium service.
|
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing cldn6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.. . Johannes Gutenberg-universitat Mainz |
The present invention pertains to novel antibodies capable of binding to cd26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing graft-versus-host disease (gvhd), for use in treating aplastic anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Adienne S.a. |
Synergistic combinations of ox40l antibodies for the treatment of gvhd The present invention relates to anti-human ox40l antibodies, new medical uses and methods.. . Kymab Limited |
The invention relates to april-binding antibodies, which bind the same epitope of human april as an antibody having an antigen binding site of hapril.01a. The antibodies of the present invention comprise specific selections of framework sequences of the vh and vl domains and have unexpected features in comparison to hapril.01a. Aduro Biotech Holdings, Europe B.v. |
The technology described herein relates to antibodies and/or polypeptides which bind to mic and inhibit mic shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein.. University Of Washington Through Its Center For Commercialization |
The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human b7-h3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized b7-h3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.. Macrogenics, Inc. |
Bispecific single chain antibodies with specificity for high molecular weight target antigens The present invention provides a method for the selection of bispecific single chain antibodies comprising a first binding domain capable of binding to an epitope of cd3 and a second binding domain capable of binding to the extracellular domain cell surface antigens with a high molecular weight extracellular domain. Moreover, the invention provides bispecific single chain antibodies produced by the use of the method of the invention, nucleic acid molecules encoding these antibodies, vectors comprising such nucleic acid molecules and methods for the production of the antibodies. Amgen Research (munich) Gmbh |
The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-cs1 antibodies in combination with one or more immunotherapeutic agents.. . Bristol-myers Squibb Company |
Methods of reducing serum levels of fc-containing agents using fcrn antagonists Provided are novel methods of reducing the serum levels of fc-containing agents (e.g., antibodies and immunoadhesins) in a subject. These methods generally comprise administering to the subject an effective amount of an isolated fcrn-antagonist that binds specifically to fcrn with increased affinity and reduced ph dependence relative to the native fc region. Argen-x N.v. |
The disclosure relates to antibodies specific to fcrn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, dna encoding the antibodies and hosts comprising said dna.. . Ucb Biopharma Sprl |
The present invention provides antibodies directed against icos or a derivative thereof which neutralize icos engagement on treg by inhibiting the fixation between icos and icos-l and abrogate proliferation of treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against icos or a derivative thereof which induce il-10 and ifnγ production, induce cd4+ t cells proliferation, reduce tconv proliferation, and increase the immunosuppressive function of treg.. Centre Leon Berard |
The present invention is directed to compositions of matter useful for the treatment of cancer in mammals and to methods of using those compositions of matter for the same. antibodies specific for podocalyxin designated ab1 and 3g2 are disclosed, as is the use of said antibodies for the inhibition of growth of a tumor that expresses podocalyxin, and the use of said antibodies for targeting tumour endothelial cells that express podocalyxin.. University Of British Columbia |
antibodies that specifically bind tem8 protein, conjugates thereof, and their use, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. Biomed Valley Discoveries, Inc. |
Provided herein is an antibody comprising an antigen binding domain which binds to human il-12 and human il-23. The antibody binds human il-12p40 existing as a monomer (human il-12p40) and as a homodimer (human il-12p80), and the antibody inhibits the binding of human il-12 to human il-12rβ2 and human il-23 to human il-23r but does not inhibit the binding of human il-12 or human il-23 or human il-12p40 or human il-12p80 to human il-12rβ1.. Teva Pharmaceuticals Australia Pty Ltd |
Il-3 blockade in systemic lupus erythematosus and multiple sclerosis The present invention relates to anti-il-3 antibodies or il-3 binding fragments thereof for use in the treatment of an autoimmune disease selected from the group consisting of systemic lupus erythematosus and multiple sclerosis, and to pharmaceutical compositions comprising such an antibody or antibody fragment.. . UniversitÄtsklinikum Regensburg |
The present invention relates to anti-tnf antibodies comprising all of the heavy chain variable cdr regions of seq id nos:1, 2 and 3 and/or all of the light chain variable cdr regions of seq id nos:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (tnf) protein or fragment thereof, as well as nucleic acids encoding such anti-tnf antibodies, complementary nucleic acids, vectors, host cells, production methods and thera. . Janssen Biotech, Inc. |
The present disclosure encompasses ngf binding proteins, specifically to antibodies that are chimeric, cdr grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting ngf and for inhibiting ngf activity, e.g., in a mammal subject suffering from a disorder in which ngf activity is detrimental.. Zoetis Belgium S.a. |
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to c5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, goodpasture's syndrome, and chronic obstructive pulmonary disease.. . Alexion Pharmaceuticals, Inc. |
Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.. . Stemcentrx, Inc. |
A glycan having the structure galβ1-3glcnacβ1-3galβ1-4(fucα1-3)glcnac (leclex) which is attached to a lipid or protein backbone, and isolated binding members capable of binding thereto.. . The University Of Nottingham |
Order a batch download of a huge number of patent PDFs.
Bulk PDF Downloads
This is a premium service.
|
The invention provides antibodies against the a2 domain of tenascin-c and methods of using the same.. . Roche Glycart Ag |
The present invention provides fully human antibodies that bind to either toxin a or toxin b of clostridium difficile, or to both toxin a and toxin b, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for neutralizing the toxins from c. Regeneron Pharmaceuticals, Inc. |
Broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibody The invention provides a method for obtaining a broadly neutralizing antibody (bnab), including screening memory b cell cultures from a donor pbmc sample for neutralization activity against a plurality of hiv-1 species, cloning a memory b cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory b cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the env proteins in native or monomeric form, as well as to inhibit infection of hiv-1 species from a plurality of clades. International Aids Vaccine Initiative |
Antibody having broad neutralization activity against group 1 influenza a viruses From pbmcs of patients infected with h1n1pdm, three human monoclonal antibodies have been obtained which are capable of binding to an epitope present at residues 40 to 58 in an ha2 region of a hemagglutinin protein derived from h1n1pdm. Further, these antibodies have been found to also have a neutralization activity against subtype h1 and subtype h5 of group 1 influenza a viruses. Department Of Medical Sciences |
The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (rbd) of the spike (s) glycoprotein of the middle east respiratory syndrome coronavirus (mers-cov). The polypeptides and fusion proteins can be used to treat and prevent mers-cov infection in mammals.. The University Of Hong Kong |
Provided is a titi monkey adenovirus (tmadv) that can infect both human and non-human primates. Further provided are nucleic acid sequences, proteins, expression vectors and host cells, anti-tmadv antibodies, vaccines, compositions, methods of detecting tmadv, methods for assaying for anti-tmadv compounds, and methods for treating or preventing a tmadv infection.. The Regents Of The University Of California |
Integrated approach to the isolation and purification of antibodies Disclosed herein is an integrated approach to purification process development and execution, including processes comprising particular capture and fine purification steps; processes that employ of a minimal number of buffer systems, and processes that make use of minimally-corrosive buffer systems, as well as combinations thereof.. . Abbvie Inc. |
Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin e (mmae) and monomethyl auristatin f (mmaf) are introduced, which have potent antitumor activity in vivo. Georgetown University |
The disclosed embodiments relate to data mining methods for determining economically valuable cause effect relationships between objects and properties associated with objects using co-occurrence frequency measurements of semantic terms characterizing observations of properties, effects or behaviors of objects in different environments and using these measurements as object descriptors in calculations determining object similarities. Specifically, these methods may be used to identify new indications of medicines, identify biomarkers associated with disease, identify biomarkers associated with drug effects, quantify disease diagnosis, identify novel drug targets, identify pharmacologic equivalencies of medicines, identify pharmacologic equivalencies between medicines and traditional medicines, identify pharmacologic equivalencies between medicines and natural products, identify equivalencies between alternate medical procedures, identify risk benefit profiles of medicine combinations, identify targets for antibodies, identify synergies between medicines, identify side effects of medicines, identify risks of experimental medicines, identify functions of biological networks.. Systamedic Inc. |
Therapeutic compositions for treating diseased cells such as cancer cells in a patient, formulated from a plurality of therapeutic agents selected from radiopharmaceuticals, chemotherapeutic agents and radionuclide labeled antibodies. Methods for predicting the response of an individual patient's cells to therapeutic intervention are also disclosed.. Rutgers, The State University Of New Jersey |
The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage ovarian cancer, in a subject by detecting bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with bcl-2 protein or a portion thereof. University Of South Florida |
The present disclosure provides high-performance immunoreagents for use in a variety of immunologic assays and other related techniques. The immunoreagents comprise a primary antibody and a bridging antigen, wherein the bridging antigen is recognized by a detectable secondary antibody with high affinity. Cell Idx, Inc. |
Antibodies that inhibit long interspersed element-1 retrotransposon endonuclease activity The present disclosure relates to monoclonal anti-line-1 orf2 protein endonuclease domain antibody, and fragments and derivatives that bind the line-1 orf2 protein endonuclease domain and inhibit its activity.. . |
The human hla-a2:1g dimer molecule is a recombinant protein comprising a mouse igg antibody fused with two human mhc class i hla-a2 molecules. Any peptide (usually 8-10 amino acids in length) can be loaded into the peptide-binding groove of the two hla molecules, for example, by incubating a mixture of the dimer and peptide solution overnight. The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Point-of-care immunosensing device for multi-biomarker detection An immunosensing device includes a hub mountable to a device for fluid collection, such as a syringe, sample collection container, or vacuum collection container, and a biosensor mounted to the hub. The biosensor includes a biosensor active area in fluid communication with a fluid passage within the hub. Northeastern University |
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. Intrexon Corporation |
An antibody comprising an antigen recognition region which comprises cdr amino acid sequences set forth in seq id no: 7, 8, 9, 10, 11 and 12.. . Yeda Research And Development Co. Ltd. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation The invention relates to glycoengineered antibodies and antibody-conjugates. In particular, the invention relates to an antibody conjugate, prepared from an igg antibody comprising one n-linked glycosylation site on the combination of a single heavy chain and single light chain, wherein the n-linked glycosylation site is a mutant n-linked glycosylation site as compared to its wild type counterpart. Synaffix B.v. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain Provided herein are isolated heteromultimers comprising: at least one single domain antigen-binding construct attached to at least one monomer of a heterodimer fc region; wherein the heterodimer fc region comprises a variant ch3 domain comprising amino acid mutations that promote the formation of said heterodimer with stability comparable to that of a native fc homodimer; and wherein said isolated heteromultimer is devoid of immunoglobulin light chains and optionally devoid of immunoglobulin ch1 region. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.. Zymeworks Inc. |
This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.. Macrogenics, Inc. |
Conjugated antibodies against ly75 for the treatment of cancer The invention provides antibodies which bind to ly75. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. Oxford Biotherapeutics Ltd |
There is disclosed compositions and methods relating to or derived from anti-jag1 antibodies. More specifically, there is disclosed fully human antibodies that bind jag1, jag1-binding fragments and derivatives of such antibodies, and jag1-binding polypeptides comprising such fragments. Sorrento Therapeutics, Inc. |
There is disclosed compositions and methods relating to or derived from anti-tim3 antibodies. More specifically, there is disclosed fully human antibodies that bind tim3, tim3-antibody binding fragments and derivatives of such antibodies, and tim3-binding polypeptides comprising such fragments. Sorrento Therapeutics, Inc. |
Method of treating stress hyperglycemia with human antibodies to the glucagon receptor The present invention provides antibodies that bind to the human glucagon receptor, designated gcgr and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human gcgr. Regeneron Pharmaceuticals, Inc. |
The present invention relates to antibodies binding specifically to ccr9, and to antigen-binding fragments thereof. It also relates to uses thereof and diagnostic methods using said antibodies.. Consejo Superior De Investigaciones CientÍficas |
The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Tracon Pharmaceuticals, Inc. |
The presently subject matter provides novel human sequence antibodies against human ctla-4 and methods of treating human diseases, infections and other conditions using these antibodies.. . E.r. Squibb & Sons, L.l.c. |
There is disclosed compositions and methods relating to or derived from anti-cd47 antibodies. More specifically, there is disclosed fully human antibodies that bind cd47, cd47-antibody binding fragments and derivatives of such antibodies, and cd47-binding polypeptides comprising such fragments. Sorrento Therapeutics, Inc. |
Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma Provided are methods for clinical treatment of multiple myeloma using an anti-kir antibody in combination with an anti-cs 1 antibody.. . Innate Pharma |
The invention provides anti-tim3 antibodies and methods of using the same.. . Hoffmann-la Roche, Inc. |
Described herein is a dimeric, bispecific antibody format. Each polypeptide chain of the dimer comprises an immunoglobulin variable region, an immunoglobulin constant region, an fc polypeptide chain, another immunoglobulin variable region, and another immunoglobulin constant region. Amgen Inc. |
The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. Rinat Neuroscience Corp. |
Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.. . Stemcentrx, Inc. |
The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region vl residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the vh of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the vl of the antibody. Genentech, Inc. |
Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.. The Regents Of The University Of Michigan |
Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies vh and/or vl domain of the scfv fragment herein termed cat-212 and of the igg4 antibody herein termed cat 213. Medimmune Limited |
The present invention relates to antibodies that bind to ctgf. The antibodies are particularly directed to regions of ctgf involved in biological activities associated with fibrosis. Fibrogen, Inc. |
Humanized and variant anti-vegf antibodies and various uses therefor are disclosed. The anti-vegf antibodies have strong binding affinities for vegf; inhibit vegf-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.. Genentech, Inc. |
The invention provides antibodies that specifically bind to transthyretin (ttr). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with ttr accumulation or accumulation of ttr deposits (e.g., ttr amyloidosis). University Health Network |
The invention provides antibodies that specifically bind to transthyretin (ttr). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with ttr accumulation or accumulation of ttr deposits (e.g., ttr amyloidosis). University Health Network |
Order a batch download of a huge number of patent PDFs.
Bulk PDF Downloads
This is a premium service.
|
The present invention provides for methods of preventing and/or treating s. Aureus-associated bacteremia and sepsis, and methods for preventing and/or treating s. Medimmune, Llc |
The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza a virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza a virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza a virus group 1 subtypes selected from h1, h2, h5, h6, h8, h9, h11, h12, h13, h16 and h17 and variants thereof and one or more influenza a virus group 2 subtype selected from h3, h4, h7, h1, 0, h14 and h15 and variants thereof.. Humabs Biomed Sa |
Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses The present invention relates to the murine monoclonal antibody (mab) 11b9 and to mab 62 each of which target major neutralizing epitopes of influenza a h7 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of h7 influenza using murine mab 11b9, mab 62 or fragments thereof. Temasek Life Sciences Laboratory Limited |
The invention relates to novel polypeptides which are recognized by anti-trichinella antibodies. Said polypeptides can be used particularly for detecting anti-trichinella antibodies and in trichinosis prevention.. Agence Nationale De Securite Sanitaire De L'alimentation, De L'environnement Et Du Travail |
Antibodies topics:
Follow us on Twitter
@FreshPatents###
This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.